Sanofi: promising study in bullous pemphigoid

(CercleFinance.com) - Sanofi reports that a pivotal study of Dupixent (dupilumab) as a treatment for bullous pemphigoid (BP) has met its primary and secondary objectives in adults with moderate to severe forms of the disease.


Five times as many patients treated with Dupixent achieved durable remission compared to placebo, says the company.

Remission was defined as the absence of relapse and discontinuation of oral corticosteroids (OCS) after 36 weeks of treatment.

Dupixent, already designated an orphan drug by the FDA, could transform the treatment of PB, a chronic disease causing disabling blistering and itching.

Bullous pemphigoid is a debilitating skin disease whose infection causes a high mortality rate. We look forward to advancing this research and reporting the positive results of the pivotal trial in bullous pemphigoid to the regulatory authorities," commented Dr. George D. Yancopoulos, Ph.D. Co-Chairman, President and Chief Scientific Officer, Regeneron.

The safety and efficacy of Dupixent in BP is currently under clinical investigation and has not been evaluated by any regulatory authority.


Copyright (c) 2024 CercleFinance.com. All rights reserved.